MSLN and neoplasm: The scRNA-seq data from respiratory system tissues indicated that pulmonary cells contained approximately 2.40% MSLN-positive cells, so the lung could be at high risk of “on-target off-tumor” toxicity for MSLN-CAR-T cell therapy.